FDA’s Online Misinformation Plan Draws Medical Industry Concerns

Medical product companies are more equipped to fight online misinformation due to recently revised FDA guidance, but the growth of independent third parties and artificial intelligence present steep hurdles for industry.

The Food and Drug Administration’s draft guidance addressing how medical product manufacturers should respond to false or misleading information on social media is expected to create a clearer path for industry after the agency earlier this year replaced a 2014 version of the guidance.

The draft update sets out an enforcement policy guiding how manufacturers, through “tailored responsive communications,” can address false, inaccurate, or misleading representations about a firm’s ...